INFI News and Press, Infinity Pharmaceuticals Inc. From 04/13/23

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib, a potential first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced upcoming presentations inc...

2023-04-03 16:41:21 ET Summary Merger arbitrage spreads are wide. There are plenty of opportunities with spreads of up to 118%. This is a review of the most interesting transactions in the merger arbitrage space. Merger arbitrage is an event-driven investment strategy of...

2023-03-28 16:48:35 ET Infinity Pharmaceuticals press release ( NASDAQ: INFI ): FY GAAP EPS of -$0.50 misses by $0.11 . Revenue of $2.59M (+39.2% Y/Y) misses by $11.31M . At December 31, 2022, Infinity had total cash and cash equivalents of $38.3 million, compa...

– Infinity ended 2022 with total cash and cash equivalents of $38.3 million – – Infinity Previously Announced Definitive Merger Agreement with MEI Pharma to Advance Three Promising Clinical Oncology Candidates – Infinity Pharmaceuticals, Inc. (NASDAQ:...

VANCOUVER, BC / ACCESSWIRE / March 15, 2023 / Infinitum Copper Corp. (TSXV:INFI)(OTCQB:INUMF) (" Infinitum " or the " Company ") is pleased to announce a private placement to raise gross proceeds of up to C$1,500,000 through the issue of up to 21,428,571 units of the Company (the " Units ") at a...

NEW YORK, NY / ACCESSWIRE / March 5, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: INDUS Realty Trust, Inc. (NASDAQ: IND...

NEW YORK, NY / ACCESSWIRE / February 26, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Jounce Therapeutics, Inc. (NAS...

Combination will create a company with a diverse product development pipeline led by a planned new global Phase 2 clinical trial evaluating eganelisib in head and neck squamous cell carcinoma (HNSCC) Projected ~$100M cash balance of combined company expected to fund operations through...

VANCOUVER, BC / ACCESSWIRE / February 22, 2023 / Infinitum Copper Corp. (TSXV:INFI)(OTCQB:INUMF) (" Infinitum " or the " Company ") is pleased to announce the successful closing of the previously announced transaction with Prismo Metals Inc. (CSE: PRIZ, OTCQB: PMOMF) ("Prismo") with respect to H...

VANCOUVER, BC / ACCESSWIRE / February 9, 2023 / Infinitum Copper Corp. (TSXV:INFI)(OTCQB:INUMF) (" Infinitum " or the " Company ") announces that Matt Hudson has been appointed as President and CEO of the Company effective February 1, 2023. Matt's operational experience in Mexico, knowledge of c...